Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ICML 2019 | Does chemotherapy still have a role in the treatment of Waldenström’s?

Steven Treon • 20 Jun 2019
ICML 2019
B-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma Rare Diseases Waldenström’s Macroglobulinemia Bortezomib Ibrutinib Rituximab Venetoclax

Does chemotherapy still have a role in the treatment of Waldenström’s? Steven Treon, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, explores this important question here at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.

More from Steven Treon

1:59
Updates in the response criteria for Waldenström’s macroglobulinemia
Steven Treon • 29 Sep 2023
2:23
Practical considerations when treating patients with WM: exciting agents & combinations
Steven Treon • 29 Sep 2023
1:54
Selecting the correct BTK inhibitor for patients with WM: lessons learned from the ASPEN trial
Steven Treon • 29 Sep 2023
1:47
Exciting updates in Waldenström’s macroglobulinemia: the value of BTK inhibitors
Steven Treon • 29 Sep 2023

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals